Exclusive: RNA delivery startup strikes partnerships with J&J and Daiichi Sankyo
Nosis Bio, a startup developing new ways to deliver RNA therapies to specific cells, has struck partnerships with two pharma companies that together could be worth more than $1.5 billion, the company told Endpoints News ...
Nosis Bio, a startup developing new ways to deliver RNA therapies to specific cells, has struck partnerships with two pharma companies that together could be worth more than $1.5 billion, the company told Endpoints News ...
